Abstracts tagged "interstitial lung disease"

Abstract Number: 038 • 2023 Pediatric Rheumatology Symposium
HLA-DRB1*15 Alleles in Systemic Juvenile Idiopathic Arthritis with Lung Disease and Macrophage Activation Syndrome in Italy
Claudia Bracaglia¹, Manuela Pardeo¹, Maria Troiano², Giuseppe Testa², Ivan Caiello¹, Arianna De Matteis³, Matteo Trevisan¹, Franco Locatelli⁴, Marco Andreani² and Fabrizio De Benedetti¹, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ²Laboratory of Transplant Immunogenetics, Department of Haematology/Oncology, Cell and Gene, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Lazio, Italy, ³Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Roma, Italy, ⁴Ospedale Pediatrico Bambino Gesù, Department of Hematology/Oncology, Cell and Gene Therapy, Roma, Italy
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is characterized by unique clinical features and it is considered as a polygenic autoinflammatory disease. Macrophage activation syndrome (MAS)…
Abstract Number: 095 • 2023 Pediatric Rheumatology Symposium
Systemic Juvenile Idiopathic Arthritis Associated Lung Disease in Europe
Claudia Bracaglia¹, Francesca Minoia², Christoph Kessel³, Sebastiaan Vastert⁴, Manuela Pardeo¹, Alessia Arduini¹, Sarka Fingerhutova⁵, Irina Nikishina⁶, Ozge Basaran⁷, Nural Kiper⁸, Mikhail Kostik⁹, Mia Glerup¹⁰, Roberta Caorsi¹¹, AnnaCarin Horne¹², Giovanni Filocamo², Helmut Wittkowski³, Marija Jelusic¹³, Jordi Anton¹⁴, Samira Khaldi-Plassart¹⁵, Alexandre Belot¹⁵, Gerd Horneff¹⁶, Seraina Palmer Sarrott¹⁷, Elvira Cannizzaro Schneider¹⁸, Lampros Fotis¹⁹, Pavla Dolezalova⁵, Angelo Ravelli²⁰, Seza Ozen⁷ and Fabrizio De Benedetti¹, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ²Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico, Milano, Italy, ³Department of Pediatric Rheumatology & Immunology, WWU Medical Center (UKM), Muenster, Germany, ⁴Wilhelmina Children’s Hospital, Department of Pediatric Immunology and Rheumatology, Utrecht, The Netherlands, Utrecht, Netherlands, ⁵Centre for Paediatric Rheumatology and Autoinflammatory Diseases, Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, ⁶V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁷Department of Pediatrics, Division of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, ⁸Department of Pediatrics, Division of Pediatric Pulmonology, Hacettepe University, Ankara, Turkey, ⁹Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, ¹⁰Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ¹¹Department of Pediatrics and Rheumatology, IRRCS Istituto G. Gaslini, Genova, Italy, ¹²Department of pediatric rheumathology Karolinska University Hospital and Department of pediatrics, Karolinska Institute, Stockholm, Sweden, ¹³Department of Paediatrics, University of Zagreb School of Medicine, University Hospital Centre, Zagreb, Croatia, ¹⁴Pediatric Rheumatology, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain, ¹⁵Pediatric Nephrology, Rheumatology, Dermatology Unit, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France, ¹⁶Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁷Paediatric Rheumatology University Children’s Hospital Zurich, Zurich, Zurich, Switzerland, ¹⁸Paediatric Rheumatology University Children’s Hospital Zurich, Zurich, Switzerland, ¹⁹Pediatric Rheumatology Division, 3rd Department of Pediatrics, National and Kapodistrian University of Athens,‘’ATTIKON’’ General University Hospital, Athens, Greece, ²⁰IRRCS Istituto Giannina Gaslini and Università degli Studi di Genova, Genova, Italy
Background/Purpose: Chronic parenchymal lung disease (LD) is a new emerging severe life-threatening complication of sJIA. The number of sJIA patients with LD is apparently increasing…
Abstract Number: 098 • 2023 Pediatric Rheumatology Symposium
Characterization of Pulmonary Nodules in Juvenile-onset Systemic Sclerosis: A Single Center Case-Series
Jonathan Li¹, Franziska Rosser¹, Sameh Tadros¹ and Kathryn Torok², ¹UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Given the high prevalence of intestinal lung disease (ILD) in systemic sclerosis (SSc) and the low sensitivity of pulmonary function testing for diagnosing ILD,…
Abstract Number: 0003 • ACR Convergence 2022
Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Disease Associated Interstitial Lung Disease (RECITAL): A Sub-group Analysis of a Multi-centre Randomised Controlled Trial
Toby Maher¹, Veronica Tudor², Peter Saunders³, Michael Gibbons⁴, Sophie Fletcher⁵, Helen Parfrey⁶, Chris Denton⁷, Rachel Hoyles³, Elizabeth Renzoni², Maria Kokosi², Athol Wells², Deborah Ashby⁸, Matyas Szigeti⁸ and Philip Molyneaux⁸, ¹University of Southern California, Los Angeles, CA, ²Royal Brompton Hospital, London, United Kingdom, ³Oxford University Hospitals, Oxford, United Kingdom, ⁴Royal Devon and Exeter Hospital, Exeter, United Kingdom, ⁵Southampton University Hospitals, Southampton, United Kingdom, ⁶Addenbrookes Hospital, Cambridge, United Kingdom, ⁷University College London, London, United Kingdom, ⁸Imperial College London, London, United Kingdom
Background/Purpose: The RECITAL trial (NCT01862926) compared rituximab to cyclophosphamide as first line therapy for patients with severe or progressive interstitial lung disease due to idiopathic…
Abstract Number: 0438 • ACR Convergence 2022
Characterization of Interstitial Lung Disease in the Presence of Antineutrophil Cytoplasmic Antibodies
Khai-Tuan Andrew Bui¹, Rachel Richard², Ariane Drouin³, Nader Toban¹, Marianne Levesque⁴, Rosalie-Selene Meunier⁵, Carolyn Ross⁶ and Jean-Paul Makhzoum³, ¹Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, ²Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Laval, QC, Canada, ³Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, ⁴Division of Respirology, Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, ⁵Hopital Sacre-Coeur, Universite de Montreal, Montréal, QC, Canada, ⁶University of Montreal, Montréal, QC, Canada
Background/Purpose: Various pulmonary manifestations may occur in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). ANCA-related interstitial lung disease (ILD) has recently been described in…
Abstract Number: 1060 • ACR Convergence 2022
Clinical Characteristics and Prognosis of Patients with Systemic Sclerosis Sine Scleroderma: Data from the International EUSTAR Database
Alain Lescoat¹, Suiyuan Huang², PATRICIA E CARREIRA³, Elise Siegert⁴, Jeska de Vries-Bouwstra⁵, Jörg Distler⁶, Vanessa Smith⁷, Branimir Anic⁸, Francesco Del Galdo⁹, Nemanja Damjanov¹⁰, Simona Rednic¹¹, camillo Ribi¹², Dominique Farge Bancel¹³, Anna-Maria Hoffmann-vold¹⁴, Armando Gabrielli¹⁵, Oliver Distler¹⁶, Dinesh Khanna¹⁷ and Yannick Allanore¹⁸, ¹CHU Rennes - University Rennes 1, Rennes, France, ²University of Michigan, Ann Arbor, MI, ³HOSPITAL 12 DE OCTUBRE, Madrid, Spain, ⁴Charité Hospital, Berlin, Germany, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁷Department of Rheumatology, Ghent University Hospital – Department of Internal Medicine, Ghent University, Belgium – Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Gent, Belgium, ⁸Clinical Hospital Centre Zagreb, School of Medicine, University of Zagreb, Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Zagreb, Croatia, ⁹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, ¹⁰Institute of Rheumatology, Belgrade, Serbia, ¹¹Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, ¹²Service of Immunology and Allergy / CHUV, Lausanne, Switzerland, ¹³Saint Louis Hospital, Paris, France, ¹⁴Oslo University Hospital, Oslo, Norway, ¹⁵Università Politecnica delle Marche, Ancona, Italy, ¹⁶Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ¹⁷Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹⁸Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France
Background/Purpose: This study aimed to characterise the main clinical features of patients with systemic sclerosis (SSc) sine scleroderma (ssSSc) in comparison with the limited cutaneous…
Abstract Number: 1520 • ACR Convergence 2022
Rituximab and Tocilizumab and Their Effect on Lung Disease Progression in Scleroderma. a Retrospective Cohort Study at a Single Centre
Nina Goldman¹, Aoife Tynan², Shivani Shah², Claire Beesley¹, Rizgar Mageed³, Chris Denton¹ and Voon Ong⁴, ¹University College London, London, United Kingdom, ²Division of Medicine, Department of Rheumatology, University College London, London, United Kingdom, ³Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom, ⁴UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality in systemic sclerosis (SSc). Emerging evidence suggests a beneficial effect of tocilizumab…
Abstract Number: 1874 • ACR Convergence 2022
Autoantibodies Are Common in Patients with Idiopathic Interstitial Lung Disease Suggesting a High Prevalence of Undiagnosed Autoimmune Connective Tissue Disease
Sarah Tansley¹, Caroline Cotton², Fionnuala McMorrow¹, Hui Lu¹, Aravinthan Loganathan¹, Zoe Betteridge¹, Robert New³, Lisa Spencer⁴, Neil McHugh¹ and Robert Cooper⁴, ¹University of Bath, Bath, United Kingdom, ²Liverpool University Hospital, Liverpool, United Kingdom, ³NCA, Manchester, ⁴University of Liverpool, Liverpool
Background/Purpose: In some patients, interstitial lung disease (ILD) may be the dominant or even sole overt manifestation of an otherwise unrecognised autoimmune connective tissue disease…
Abstract Number: 0035 • ACR Convergence 2022
Anti-Peroxiredoxin 6 and Anti- Myosin Light Polypeptide 6 Autoantibodies with Interstitial Lung Disease and Severe Disease in Juvenile Dermatomyositis
Rie Karasawa¹, James Jarvis², Toshiko Sato¹, Megumi Tanaka¹, Terrance P O'Hanlon³, Payam Noroozi-Farhadi⁴, Willy A. Flegel⁵, Kazuo Yudoh¹ and Lisa G Rider³, ¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, ²Department of Pediatrics, University at Buffalo Clinical and Translational Research Center, Buffalo, NY, ³Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, ⁴NIEHS, NIH, Garrett Park, MD, ⁵NIH, Garrett Park, MD
Background/Purpose: Juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM) are among the most common forms of inflammatory rheumatic diseases in children. Anti-endothelial cell antibodies (AECA)…
Abstract Number: 0508 • ACR Convergence 2022
Detecting the Critical Factors in the Pathogenesis of Anti-melanoma Differentiation-associated Gene 5–positive Dermatomyositis (MDA5 DM) by Gene Expression Analysis of Peripheral Blood
Yoshinobu Koyama¹, Yoshiharu Sato², Yu Nakai¹ and Moe Sakamoto¹, ¹Japanese Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc, Tokyo, Japan
Background/Purpose: MDA5 DM is a distinct subtype of DM that is characterized by high mortality due to rapid progressive interstitial lung disease (ILD). MDA5 is…
Abstract Number: 1062 • ACR Convergence 2022
Lung Magnetic Resonance Imaging in Systemic Sclerosis Associated Interstitial Lung Disease: Potentiality and Comparison with Other Imaging Techniques
Marco Di Battista¹, Chiara Romei², Simone Barsotti¹, Mattia Da Rio³, Giammarco De Mattia³, Alessio Milazzo², Annalisa De Liperi², Alessandra Della Rossa³ and Marta Mosca¹, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²Radiology Unit, University of Pisa, Pisa, Toscana, Italy, ³Rheumatology Unit, University of Pisa, PISA, Toscana, Italy
Background/Purpose: Interstitial lung disease (ILD) is one of the most severe complications in systemic sclerosis (SSc). The diagnosis and monitoring of ILD is based on…
Abstract Number: 1524 • ACR Convergence 2022
Risk Factors for Lung Function Decline in Systemic Sclerosis Interstitial Lung Disease in a Large Single-Center Cohort
Ahmad Ramahi¹, Alain Lescoat², David Roofeh¹, Vivek Nagaraja¹, Rajaie Namas³, Suiyuan Huang¹, John Varga¹, David O’Dwyer¹, Bonnie Wang¹, Kevin Flaherty¹, Ella Kazerooni¹ and Dinesh Khanna⁴, ¹University of Michigan, Ann Arbor, MI, ²CHU Rennes - University Rennes 1, Rennes, France, ³Medical Subspecialties Institute, Division of Rheumatology at Cleveland Clinic, Abu Dhabi, United Arab Emirates, ⁴Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is the leading cause of scleroderma-related mortality. This work identifies factors associated with SSc-ILD decline on pulmonary function…
Abstract Number: 1959 • ACR Convergence 2022
Increased Mortality in Patients with RA-Associated Interstitial Lung Disease: Data from a French Administrative Healthcare Database
Pierre-Antoine Juge¹, Lidwine Wemeau², Sebastien Ottaviani³, guillaume desjeux⁴, Joe Zhuo⁵, Virginie Vannier-Moreau⁶, René-Marc Flipo⁷, Bruno Crestani⁸ and Philippe Dieude⁹, ¹Rheumatology department, Bichat Hospital, Paris, France, ²Pulmonology department, Lille University hospital, Lille, France, ³Hopital Bichat-Claude Bernard, Paris, France, ⁴e-Health Services Sanoia, Gemenos, France, ⁵BMS, Lawrenceville, NJ, ⁶BMS, Rueil-Malmaison, ⁷Hôpital Roger Salengro, Lille, France, ⁸Hopital Bichat, Paris University, Paris, France, ⁹Université Paris Cité, Paris, France
Background/Purpose: Interstitial lung disease (ILD) is a common extra-articular manifestation of RA. Studies have shown variability in the prevalence and mortality rate of patients with…
Abstract Number: 0048 • ACR Convergence 2022
Combination of Repetitive Inhalant Endotoxin Exposure and Collagen-induced Arthritis Interact in a Testosterone-dependent Manner to Drive Inflammatory Lung Disease Processes and Arthritis Severity in Mice
Elizabeth Ramler¹, Ted Mikuls², Geoffrey Thiele³, Amy Nelson³, Michael Duryee³, Rohit Gaurav³, Todd Wyatt¹, Aaron Schwabb³, carlos hunter³, Bryant England³ and Jill Poole³, ¹University of Nebraska Medical Center, Omaha, ²Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Respiratory-related diseases are among the most common causes of death in rheumatoid arthritis (RA). Although autoimmune diseases are reported in higher frequency in females,…
Abstract Number: 0520 • ACR Convergence 2022
Combination Therapy of Mycophenolate Mofetil and Pirfenidone vs. Mycophenolate Alone: Results from the Scleroderma Lung Study III
Dinesh Khanna¹, Cathie Spino², Elana Bernstein³, Jonathan Goldin⁴, Donald Tashkin⁴, Michael roth⁴ and On Behalf of SLS III Investigators², ¹Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Columbia University, New York, NY, ⁴University of California Los Angeles, Los Angeles, CA
Background/Purpose: Scleroderma Lung Study (SLS) II established mycophenolate mofetil (MMF) as an active therapy for scleroderma-related interstitial lung disease (SSc-ILD) and the need to consider…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].